RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy

Recruiting Phase 2 Interventional Study
Vomiting in Infants and/or Children Nausea Hematopoietic System--Cancer Oncology
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
30 Months – 18
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Supportive Care
Participants needed
200 (estimated)
Sponsor
The Hospital for Sick Children · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving hematopoietic stem cell transplant (HSCT) conditioning, experience CIV despite receiving antiemetic prophylaxis. Olanzapine improves CINV control in adult cance…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Planned receipt of HEC or cyclophosphamide ≥ 1 g/m2/day (≥ 33 mg/kg/day) for cancer treatment or autologous or allogeneic HSCT conditioning.81,82 Examples of HEC are: busulfan IV (myeloablative dosing), carboplatin ≥175mg/m²/dose, cisplatin ≥12mg/m²/dose, cytarabine ≥3g/m²/day, melphalan \>140mg/m²,…
Contacts

Lee Dupuis, RPh, PhD

416-813-7762

lee.dupuis@sickkids.ca

CONTACT

Muhammad Ali, MD

416-813-7654

muhammad.ali@sickkids.ca

CONTACT